Immunopharmacologic profile of nedocromil sodium.

Abstract

Nedocromil sodium, a pyranoquinolone, was specifically designed as an agent to suppress allergic inflammation. Nedocromil sodium significantly affects not only the early-phase of allergen-induced responses, but also expression of late-phase inflammation, even when administered after the onset of early-phase responses. Nedocromil sodium also limits bronchoconstriction induced by nonallergic factors, including cold air and sulfur dioxide at dosages lower than required with cromolyn sodium. Nedocromil sodium is more potent than cromolyn sodium in preventing mast cell degranulation in selective animal models. In addition, nedocromil sodium limits leukotriene C4 production by calcium ionophore-stimulated eosinophils and also limits the activity of platelet activating factor to induce neutrophil generation of superoxides. Diurnal variation of peak flow rates in asthmatics and requirement for both beta 2-agonists and inhaled beclomethasone have been noted to be reduced in several trials employing nedocromil sodium, suggesting that its in vivo activity parallels its in vitro activity as an anti-inflammatory agent.